X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (88) 88
cyp17a1 (74) 74
humans (69) 69
male (50) 50
prostate cancer (49) 49
steroid 17-alpha-hydroxylase - metabolism (35) 35
steroidogenesis (33) 33
cytochrome p-450 (32) 32
abiraterone (31) 31
biochemistry & molecular biology (29) 29
animals (28) 28
steroid 17-alpha-hydroxylase - genetics (28) 28
androgens (25) 25
endocrinology & metabolism (24) 24
steroid 17-alpha-hydroxylase - antagonists & inhibitors (24) 24
cyp17a1 inhibition (22) 22
abiraterone acetate (21) 21
article (21) 21
female (20) 20
oncology (20) 20
prostatic neoplasms - drug therapy (19) 19
testosterone (18) 18
androgen receptor (17) 17
analysis (14) 14
cell line, tumor (14) 14
cytochrome p450 (14) 14
physiological aspects (14) 14
antitumor-activity (13) 13
mice (13) 13
prostatic neoplasms - metabolism (13) 13
enzymes (12) 12
gene expression (12) 12
prostatic neoplasms - pathology (12) 12
androstenes (11) 11
cancer (11) 11
progesterone (11) 11
research (11) 11
resistant prostate-cancer (11) 11
castration (10) 10
cyp17a1 inhibitors (10) 10
disease progression (10) 10
expression (10) 10
increased survival (10) 10
metabolism (10) 10
mutation (10) 10
prostatic neoplasms, castration-resistant - drug therapy (10) 10
receptors, androgen - metabolism (10) 10
steroids (10) 10
androstenes - pharmacology (9) 9
genetic aspects (9) 9
pharmacology & pharmacy (9) 9
acetate (8) 8
androgen-receptor (8) 8
dihydrotestosterone (8) 8
endocrine system (8) 8
genotype (8) 8
growth (8) 8
polymorphism, single nucleotide (8) 8
prostate (8) 8
prostatic neoplasms - genetics (8) 8
steroid 17-alpha-hydroxylase - chemistry (8) 8
urologic and male genital diseases (8) 8
androgen antagonists - therapeutic use (7) 7
androgens - metabolism (7) 7
androstenols - pharmacology (7) 7
cells (7) 7
cells, cultured (7) 7
chemotherapy (7) 7
congenital adrenal-hyperplasia (7) 7
corticosteroids (7) 7
drug therapy (7) 7
gene (7) 7
health aspects (7) 7
i clinical-trial (7) 7
inhibition (7) 7
progression (7) 7
prostate-cancer (7) 7
rats (7) 7
rats, sprague-dawley (7) 7
receptor (7) 7
androgen (6) 6
antineoplastic agents - therapeutic use (6) 6
biosynthesis (6) 6
care and treatment (6) 6
case-control studies (6) 6
castration resistant prostate cancer (6) 6
castration-resistant prostate cancer (6) 6
cholesterol (6) 6
men (6) 6
metabolites (6) 6
molecular docking simulation (6) 6
steroid hormones (6) 6
toxicology (6) 6
treatment outcome (6) 6
urology & nephrology (6) 6
xenograft model antitumor assays (6) 6
17,20-lyase activity (5) 5
3-hydroxysteroid dehydrogenases - metabolism (5) 5
aged (5) 5
androgens - biosynthesis (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 01/2017, Volume 16, Issue 1, pp. 35 - 44
Abiraterone suppresses intracrine androgen synthesis via inhibition of CYP17A1. However, clinical evidence suggests that androgen synthesis is not fully... 
STEROIDOGENIC ENZYME AKR1C3 | CYP17A1 INHIBITION | ONCOLOGY | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | 17-BETA-HYDROXYSTEROID-DEHYDROGENASE AKR1C3 | INCREASED SURVIVAL | ENZALUTAMIDE RESISTANCE | ANTITUMOR-ACTIVITY | ANDROGEN RECEPTOR GENE | EXPRESSION | 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE | Prostatic Neoplasms - metabolism | Humans | Receptors, Androgen - metabolism | Gene Expression Regulation, Neoplastic | Male | Androstenes - pharmacology | Hydroxyprostaglandin Dehydrogenases - metabolism | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Prostatic Neoplasms - genetics | Cell Transformation, Neoplastic - genetics | 3-Hydroxysteroid Dehydrogenases - metabolism | Transcription, Genetic | Prostatic Neoplasms - drug therapy | Disease Models, Animal | Prostatic Neoplasms - pathology | Gene Expression | Antineoplastic Agents, Hormonal - pharmacology | Cell Transformation, Neoplastic - metabolism | Hydroxyprostaglandin Dehydrogenases - genetics | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Animals | Aldo-Keto Reductase Family 1 Member C3 | Cell Line, Tumor | Mice | Cell Transformation, Neoplastic - drug effects | 3-Hydroxysteroid Dehydrogenases - genetics | Neoplasm Staging | Medical research | Transcription | Medical services | Clinical trials | Activation | Signaling | Androgens | Synthesis | Steroidogenesis | Indomethacin | Inhibition | Prostate cancer | Prostate | Cancer | Index Medicus | AKR1C3 | prostate cancer | intracrine androgens | abiraterone | indomethacin
Journal Article
Steroids, ISSN 0039-128X, 07/2019, Volume 147, pp. 10 - 18
A number of isoxazole, 1,2,3-triazole, tetrazole, and 1,2,4-oxadiazole derivatives of [17(20) ]-21-norpregnene comprising 3β-hydroxy-5-ene and 3-oxo-4-ene... 
Azoles | CYP17A1 inhibitors | PC-3 prostate carcinoma cells | [17E]-21-Norpregnenes | LNCaP prostate carcinoma cells
Journal Article
Journal of Ovarian Research, ISSN 1757-2215, 02/2014, Volume 7, Issue 1, pp. 21 - 21
Journal Article
Journal Article
Nature, ISSN 0028-0836, 07/2015, Volume 523, Issue 7560, pp. 347 - 351
Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability of converting precursor steroids to 5... 
ANDROGEN RECEPTOR | 3-BETA-HYDROXYSTEROID DEHYDROGENASE | CYP17A1 INHIBITION | MECHANISM | TESTOSTERONE | RATIONALE | MULTIDISCIPLINARY SCIENCES | INCREASED SURVIVAL | CHEMOTHERAPY | EXPOSURE | ENZALUTAMIDE | Chromatin - metabolism | Prostatic Neoplasms - metabolism | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Androgen Receptor Antagonists - therapeutic use | Humans | Receptors, Androgen - metabolism | Gene Expression Regulation, Neoplastic | Androgens - biosynthesis | Male | Androstenes - pharmacology | Androgen Receptor Antagonists - pharmacology | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Biotransformation | Cell Division | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - metabolism | 3-Hydroxysteroid Dehydrogenases - metabolism | Prostatic Neoplasms - drug therapy | Dihydrotestosterone - metabolism | Phenylthiohydantoin - pharmacology | Prostatic Neoplasms - pathology | Androstenes - therapeutic use | 5-alpha Reductase Inhibitors - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Phenylthiohydantoin - analogs & derivatives | Androgen Receptor Antagonists - metabolism | Xenograft Model Antitumor Assays | Androstenes - chemistry | Animals | Biosynthetic Pathways - drug effects | Survival Analysis | 5-alpha Reductase Inhibitors - pharmacology | Androstenes - metabolism | Prostatic Neoplasms - enzymology | Mice | Steroid 17-alpha-Hydroxylase - metabolism | 5-alpha Reductase Inhibitors - metabolism | Androgens - metabolism | Enzymes | Testosterone | Androgens | Metabolites | Ligands | Gene expression | Prostate cancer | Tumors | Index Medicus
Journal Article
PROSTATE, ISSN 0270-4137, 05/2017, Volume 77, Issue 6, pp. 654 - 671
BACKGROUNDMetastatic prostate cancer is a common and lethal disease for which there are no therapies that produce cures or long-term durable remissions.... 
GENE-MUTATIONS | SURVIVAL | MITOXANTRONE | patient-derived xenografts | bone response | prostate cancer | TUMOR XENOGRAFTS | CYP17A1 INHIBITION | MEN | ENDOCRINOLOGY & METABOLISM | RESISTANCE | UROLOGY & NEPHROLOGY | response to castration | EXPRESSION | ABIRATERONE | ENZALUTAMIDE
Journal Article
Nature, ISSN 0028-0836, 05/2016, Volume 533, Issue 7604, pp. 547 - 551
Abiraterone blocks androgen synthesis and prolongs survival in patients with castration-resistant prostate cancer, which is otherwise driven by intratumoral... 
ACTIVATION | CYP17A1 INHIBITION | RAT | MULTIDISCIPLINARY SCIENCES | ANDROGEN-RECEPTOR | BIOLOGY | MEN | RESISTANCE | STEROID 5-ALPHA-REDUCTASE | DIHYDROTESTOSTERONE | DEHYDROGENASE | Prostatic Neoplasms - metabolism | Dutasteride - therapeutic use | Humans | Receptors, Androgen - metabolism | Androgens - biosynthesis | Male | Androstenes - pharmacology | Abiraterone Acetate - administration & dosage | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - metabolism | Oxidation-Reduction - drug effects | Prostatic Neoplasms - blood | Androstenes - blood | Prostatic Neoplasms - drug therapy | Administration, Oral | Prostatic Neoplasms, Castration-Resistant - blood | Androgen Antagonists - pharmacology | 5-alpha Reductase Inhibitors - therapeutic use | Abiraterone Acetate - therapeutic use | Dutasteride - pharmacology | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androstenes - administration & dosage | Prostatic Neoplasms, Castration-Resistant - metabolism | Disease Progression | Xenograft Model Antitumor Assays | Animals | Abiraterone Acetate - blood | Abiraterone Acetate - metabolism | 5-alpha Reductase Inhibitors - pharmacology | Androgen Antagonists - therapeutic use | Androstenes - metabolism | Cell Line, Tumor | Mice | Physiological aspects | Prostate cancer | Care and treatment | Enzymes | Androgens | Metabolites | Oxidation | Metabolism | Gene expression | Steroids | Index Medicus
Journal Article